Although Pfizer's statement in its 10Q seems to cast doubt on the future of the Remoxy program, a letter from Alan H. Litwack, vice president of global commercial development for Pfizer to Pain Therapeutics, dated May 9, seems much more optimistic

said Rosamond Deegan, vice president of business development for King of Prussia, Pa.-based Trevena

David Miller, executive vice president and CEO of the International Academy of Compounding Pharmacy, objected to an exemption for hospital compounders, pointing out that hospital systems cross state lines and are not confined to the traditional brick and mortar operations of the past...Kasey Thompson, vice president of the Office of Policy, Planning and Communications at the American Society of Health-System Pharmacists, held out for the hospital exemption, saying hospital compounders vs

Clive Morris, vice president of R&D at AstraZeneca, said Redx's move "is an important first step in our ambition to secure a sustainable future for the site

Addex Therapeutics SA, of Geneva, disclosed positive preclinical data for its GABAB receptor-positive allosteric modulator in a rodent model of chronic alcohol dependence. The Addex alcoholism candidate, ADX71441, demonstrated robust and dose-dependent suppression of alcohol intake in animals lasting 24 hours. ADX71441 is an oral small molecule, with potential for once-daily dosing. In other news, Addex said dipraglurant demonstrated dose-dependent mGlu5 receptor occupancy in a nonhuman primate

Andrew Robbins, vice president of commercial operations for Array, noted that Novartis is scheduled to commence the NRAS melanoma trial "momentarily," and its data would be filed as a registration study, so that the ovarian trial's results would be part of a supplemental new drug application, if all goes well

Quest Diagnostics Inc., of Madison, N.J., appointed Jim Davis senior vice president, diagnostic solutions...Vanda Pharmaceuticals Inc., of Washington, named Paolo Baroldi senior vice president and chief medical officer

Andrei Gudkov, who is chief scientific officer at Cleveland BioLabs as well as senior vice president of basic science at the Roswell Park Cancer Institute and the paper's corresponding author, told BioWorld Today that after the fact, "from an engineering perspective, it makes sense" that TLR5 agonists should work in the liver, though he also cheerfully acknowledged the findings were at first surprising to him and his colleagues

Specific details were not provided, but Craig Audet, senior vice president of operations and head of global regulatory affairs, cited nonclinical issues

In granting the motion, the judge ruled that the plaintiffs failed to offer any reliable evidence that Mr. Cooper's disease was caused by Actos (pioglitazone HC1)," said Kenneth D. Greisman, senior vice president, general counsel, Takeda Pharmaceuticals U.S.A. Inc

His own background includes tenure as a senior vice president at Merck

We see ourselves as an enabler." – Stacy Davis, Vice President, Ortho Clinical Diagnostics No Stand-up Comedy, but 15 Minutes on Stage One-on-one partnering has gained momentum at the BIO International Convention, with many participants never setting foot in a breakout session...During a Tuesday session included as part of the orphan disease forum, Rogerio Vivaldi, senior vice president and head of the rare disease unit at Sanofi SA subsidiary Genzyme, recounted the moment 21 years ago when he was

Although Procysbi is dosed in a weight-based fashion and priced per milligram, the company estimated the average cost per patient per year will be $250,000, according to Julie Anne Smith, executive vice president of strategy and chief operating officer

The price points, frankly, at some point are going to be unsustainable," said Sunil Patel, senior vice president and chief business officer of Oncomed Pharmaceuticals Inc

asked George Golumbeski, senior vice president of business development for Celgene Corp...At the end of the day, clinical data will trump biomarkers," said Mark Miller, vice president of corporate business development for Eli Lilly and Co

asked George Golumbeski, senior vice president of business development for Celgene Corp...At the end of the day, clinical data will trump biomarkers," said Mark Miller, vice president of corporate business development for Eli Lilly and Co

Fox and Mike Rivard, Avaxia's vice president of corporate development, scheduled three full days of one-on-one meetings at BIO

Marc Boutin, executive vice president of the National Health Council in Washington, offered a more colorful description of that imbalance

The government has come a long ways since 9/11, but we have a long way to go," Francesca Cook, senior vice president of policy and government affairs at PharmAthene Inc., told BioWorld Insight...That wasn't economical using the transgenic goat platform," explained John Troyer, PharmAthene's vice president of chemical defense product development